Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.

NovaBridge Biosciences and Visara have announced topline results from their phase 2a study of VIS-101 for retinal vascular ...

An FDA complete response letter for idebenone in LHON indicates unresolved NDA deficiencies and necessitates additional data before approval can be reconsidered. Priority review status and a February ...

Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...

US News evaluated freestanding ASCs only, excluding hospital-affiliated outpatient departments to avoid overlap with hospital rankings and maintain comparability across facility types. Methodology ...

Aldeyra plans to request a Type A meeting and currently does not intend further clinical trials, asserting rapid-onset activity within minutes versus existing therapies requiring weeks to months.

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

Management prioritizes 5%–10% weight loss and acetazolamide titration guided by Frisén grading, OCT, and visual fields; refractory or vision-threatening disease may need ONSF or CSF shunting.

The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 ...

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Cross-sectional analysis of the prospective Low Vision Rehabilitation Outcomes Study included 28 US centers and assessed pre/post rehabilitation function using the Activity Inventory general ...